Biogen bets big on Sangamo's zinc fingers to treat Alzheimer's

Friday, February 28, 2020 - 16:50 in Health & Medicine

Biogen will pay the biotech firm $350 million upfront and get rights to its therapies for up to 12 neurological diseases

Read the whole article on C&EN

More from C&EN

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net